Search results
Showing 31 to 45 of 257 results for carcinoma
Metastatic malignant disease of unknown primary origin in adults: diagnosis and management (CG104)
This guideline covers diagnosing and managing secondary cancer in people aged 18 and over when the site of the primary cancer is unknown. This includes people who have had treatment for cancer before. It aims to improve quality of life by offering advice on tests for identifying the site of the primary cancer and options for managing the person’s condition.
This quality standard covers preventing, assessing, diagnosing and managing skin cancer (melanoma and non-melanoma skin cancer). It describes high-quality care in priority areas for improvement.
View quality statements for QS130Show all sections
Sections for QS130
Everolimus for advanced renal cell carcinoma after previous treatment (TA432)
Evidence-based recommendations on everolimus (Afinitor) for advanced renal cell carcinoma after previous treatment.
This quality standard covers identifying, assessing and managing chronic liver disease in children, young people and adults, and cirrhosis in young people and adults. It describes high-quality care in priority areas for improvement.
View quality statements for QS152Show all sections
Sections for QS152
- Quality statements
- Quality statement 1: Advice on physical activity, diet and alcohol
- Quality statement 2 (developmental): Testing for advanced liver fibrosis
- Quality statement 3 (developmental): Non-invasive testing for cirrhosis
- Quality statement 4: Surveillance for hepatocellular carcinoma
- Quality statement 5: Prophylactic intravenous antibiotics for upper gastrointestinal bleeding
- Update information
- About this quality standard
NICE is unable to make a recommendation about the use in the NHS of pembrolizumab (Keytruda) for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy. This is because Merck Sharp & Dohme UK Ltd did not provide an evidence submission
Show all sections
Sections for TA570
Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma (TA169)
Evidence-based recommendations on sunitinib (Sutent) for untreated advanced or metastatic renal cell carcinoma in adults.
Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma (TA666)
Evidence-based recommendations on atezolizumab (Tecentriq) with bevacizumab (Avastin) for treating advanced or unresectable hepatocellular carcinoma in adults who have not had previous systemic treatment.
Selective internal radiation therapies for treating hepatocellular carcinoma (TA688)
Evidence-based recommendations on selective internal radiation therapies SIR-Spheres (Sirtex), TheraSphere (BTG) and QuiremSphere (Quirem Medical) for treating hepatocellular carcinoma in adults.
Avelumab with axitinib for untreated advanced renal cell carcinoma (TA1120)
Evidence-based recommendations on avelumab (Bavencio) with axitinib for untreated advanced renal cell carcinoma in adults.
Awaiting development Reference number: GID-TA11161 Expected publication date: TBC
Awaiting development Reference number: GID-TA10911 Expected publication date: TBC
Evidence-based recommendations on durvalumab (Imfinzi) with tremelimumab (Imjudo) for untreated advanced or unresectable hepatocellular carcinoma in adults.
This guideline covers diagnosing and managing bladder cancer in people 18 and above referred from primary care with suspected bladder cancer, and those with newly diagnosed or recurrent bladder (urothelial carcinoma, adenocarcinoma, squamous-cell carcinoma or small-cell carcinoma) or urethral cancer.
Awaiting development Reference number: GID-TA11019 Expected publication date: TBC
This quality standard covers assessing, diagnosing and managing head and neck cancer, including cancer of the upper aerodigestive tract in people aged 16 or over. It describes high-quality care in priority areas for improvement.